Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1978 Sep;14(3):281–283. doi: 10.1128/aac.14.3.281

Pharmacokinetics of Cefaclor in Patients with End Stage Renal Disease and During Hemodialysis

S J Berman 1, W H Boughton 2, J G Sugihara 1,2, E G C Wong 1,2, M M Sato 2, A W Siemsen 1,2
PMCID: PMC352452  PMID: 708006

Abstract

A single 1.0-g dose of cefaclor administered to patients with stable end stage renal disease whose creatinine clearances were <5 ml/min produced a mean peak serum concentration of 48.3 ± 19.8 μg/ml. The half-life was 2.3 ± 0.3 h. Hemodialysis shortened the half-life of a similar dose to 1.6 ± 0.3 h. Approximately one-third (340 mg) of the administered drug was recovered in the dialysate. Multiple doses of 500 mg every 6 h between hemodialysis sessions produced effective serum concentrations and no bioassay evidence of drug accumulation.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bill N. J., Washington J. A., 2nd Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrob Agents Chemother. 1977 Mar;11(3):470–474. doi: 10.1128/aac.11.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Foglesong M. A., Lamb J. W., Dietz J. V. Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic. Antimicrob Agents Chemother. 1978 Jan;13(1):49–52. doi: 10.1128/aac.13.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kabins S. A., Kelner B., Walton E., Goldstein E. Cephalexin therapy as related to renal function. Am J Med Sci. 1970 Feb;259(2):133–142. doi: 10.1097/00000441-197002000-00007. [DOI] [PubMed] [Google Scholar]
  4. Kunin C. M., Finkelberg Z. Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients. Ann Intern Med. 1970 Mar;72(3):349–356. doi: 10.7326/0003-4819-72-3-349. [DOI] [PubMed] [Google Scholar]
  5. Linquist J. A., Siddiqui J. Y., Smith I. M. Cephalexin in patients with renal disease. N Engl J Med. 1970 Oct 1;283(14):720–723. doi: 10.1056/NEJM197010012831402. [DOI] [PubMed] [Google Scholar]
  6. Reisberg B. E., Mandelbaum J. M. Cephalexin: absorption and excretion as related to renal function and hemodialysis. Infect Immun. 1971 Apr;3(4):540–543. doi: 10.1128/iai.3.4.540-543.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Sanders C. In vitro studies with cefaclor, a new oral cephalosporin. Antimicrob Agents Chemother. 1977 Oct;12(4):490–497. doi: 10.1128/aac.12.4.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Santoro J., Levison M. E. In vitro activity of cefaclor, a new orally administered cephalosporin antibiotic. Antimicrob Agents Chemother. 1977 Sep;12(3):442–443. doi: 10.1128/aac.12.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES